<DOC>
	<DOCNO>NCT02822573</DOCNO>
	<brief_summary>This study compare safety effect donepezil ( Aricept ) decrease memory loss receive chemotherapy breast cancer .</brief_summary>
	<brief_title>Phase 3 Randomized Placebo Controlled Clinical Trial Donepezil - WF 97116</brief_title>
	<detailed_description>A randomize , placebo control , double-blind , parallel group Phase 3 design use assess effect 24 week donepezil cognitive function ( memory ) breast cancer survivor report cognitive dysfunction demonstrate memory impairment 1-5 year post chemotherapy . Patients meet eligibility criterion stratify age ( &lt; 50 , 50-59 , 60-69 , ≥70 ) randomize donepezil placebo equal probability .</detailed_description>
	<mesh_term>Donepezil</mesh_term>
	<criteria>Women ≥18 year old history invasive breast cancer Must complete least 4 cycle adjuvant/neoadjuvant cytotoxic chemotherapy 1 5 year prior registration ( Ongoing herceptin chronic HER 2 direct therapy allow ) . Patients receive ongoing hormonal therapy breast cancer must hormonal agent least 3 month prior study registration plan continue duration study ( 9 month ) Use psychotropic medication ( antidepressant , anxiolytic , sleep aid , narcotic ) permit ( patient ask list take within last 3 day recent medication sheet ) dose stable previous 12 week . Selfreported cognitive problem plus measured memory deficit ( score &lt; 7 single trial Eligibility Prescreen HVLTR Form C ) . Prior treatment &gt; 4 cycle adjuvant/neoadjuvant cytotoxic chemotherapy ECOG performance status 02 Ability understand willingness sign write informed consent document . Must able speak English . Evidence suspect recurrent metastatic disease . Prior brain irradiation allow . Patients may currently take Ketoconazole Quinidine History dementia , Alzheimer 's disease , multiinfarct dementia CVA ( history transient ischemic attack ( TIA allow ) . Current use donepezil , galantamine , rivastigmine , tacrine , memantine , methylphenidate , dextroamphetamine , specific cognition enhance drug allow . For patient used medication must use within 4 week prior registration . History allergic reaction attribute compound similar chemical biologic composition donepezil . Hypersensitivity donepezil . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , recent myocardial infarction , cardiac arrhythmia . Traumatic brain injury , multiple sclerosis , acute severe fatigue , chronic fatigue syndrome fibromyalgia . Psychiatric illness/social situation would limit compliance study requirement include limited history schizophrenia , psychosis substance abuse . Untreated current severe depression . Currently treat depression permit treatment stable . Pregnant woman exclude study . The effect donepezil develop human fetus recommend therapeutic dose unknown . For reason donepezil know teratogenic , woman childbearing potential must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration study participation . Should woman become pregnant suspect pregnant participating study , inform study physician immediately . It unknown whether donepezil excrete breast milk , reason woman currently breastfeed eligible study .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>